[Federal Register Volume 80, Number 191 (Friday, October 2, 2015)]
[Notices]
[Page 59794]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24988]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Start-Up Exclusive License: Differential 
Expression of Molecules Associated With Acute Stroke

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health (NIH), Department of 
Health and Human Services, is contemplating the grant of a start-up 
exclusive license to VuEssence, which is located in Florida, to 
practice the inventions embodied in the following patents:

1. AU Patent 2005248410, issued August 5, 2010 (E-306-2003/0-AU-03)
2. US Patent 7,749,700, issued July 6, 2010 (E-306-2003/1-US-01)

    The patent rights in these inventions have been assigned to the 
United States of America. The prospective start-up exclusive license 
territory may be worldwide and the field of use may be limited to in 
vitro class III diagnostic device for the detection and assessment of 
ischemic stroke in humans.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
October 19, 2015 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated start-up 
exclusive evaluation option license should be directed to: Susan Ano, 
Ph.D., NINDS Technology Transfer and Development Branch, 31 Center 
Drive, Suite 8A52, MS2540, Bethesda, MD 20892; Telephone: (301) 435-
5515; Email: [email protected].

SUPPLEMENTARY INFORMATION: The present technology claims methods of 
determining whether a subject had an ischemic stroke by detecting 
expression of twenty biomarkers in the blood, comparing expression 
levels to an individual who has not had a stroke, and determining 
whether there was at least a four-fold increase in the biomarker 
expression levels. Each of the biomarkers is detectable by a specified 
set of sequences.
    The patent also claims a method of administering an appropriate 
treatment regimen for a subject who had an ischemic stroke.
    The prospective start-up exclusive license may be granted unless 
within fifteen (15) days from the date of this published notice, the 
NIH receives written evidence and argument that establishes that the 
grant of the license would not be consistent with the requirements of 
35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the field of use filed in 
response to this notice will be treated as objections to the grant of 
the contemplated start-up exclusive license. Comments and objections 
submitted to this notice will not be made available for public 
inspection and, to the extent permitted by law, will not be released 
under the Freedom of Information Act, 5 U.S.C. 552.

    Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-24988 Filed 10-1-15; 8:45 am]
 BILLING CODE 4140-01-P